5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy
    Meeting Abstract

    Shah, N. J.; Campbell, M. T.; Mao, S.; Ornstein, M. C.; Haas, N. B.; Gao, X.; Hammers, H.; Keshava-Prasad, H.; Hoimes, C. J.; Hussain, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)
    Meeting Abstract

    Voss, M. H.; Garmezy, B.; Kim, S. H.; Rey, J. P. M.; Mansinho, A. B.; Rodriguez-Vida, A.; Oliveira, J.; van Dongen, M.; Medina Rodríguez, L.; Negrier, S.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Assessing PSA
    Meeting Abstract

    Halabi, S.; Roy, A.; Guo, S.; Rydzewska, L.; Godolphin, P. J.; Parmar, M. K.; Hussain, M.; Tangen, C.; Thompson, I. M.; Carducci, M. A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Prognostic value of neutrophil-to-lymphocyte ratio and lymphopenia in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with [177Lu]Lu-PSMA-617: VISION post hoc analysis
    Meeting Abstract

    Wei, X. X.; Chi, K. N. N.; de Bono, J. S.; Fizazi, K.; Krause, B.; Herrmann, K.; Rahbar, K.; Tagawa, S. T.; Morris, M. J.; Meisel, A.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Cancer premium: Explaining differences in prices for cancer vs non-cancer drugs with efficacy and epidemiological endpoints in the US, Germany, and Switzerland
    Meeting Abstract

    Serra-Burriel, M.; Perényi, G.; Laube, Y.; Mitchell, A.; Vokinger, K. N.
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Kelly, W.; Danila, D.; Lin, C. C.; Lee, J. L.; Matsubara, N.; Ward, P.; Armstrong, A. J.; Pook, D.; Kim, M.; Dorff, T.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of niraparib and abiraterone acetate plus prednisone (NIRA+AAP) in homologous recombination repair gene-altered (HRR+) metastatic castration-resistant prostate cancer (mCRPC) by tissue and/or plasma assays in the MAGNITUDE trial
    Meeting Abstract

    Attard, G.; Sandhu, S. K.; Rathkopf, D.; Castro, E.; Saad, M.; Smith, M. R.; Small, E. J. J.; Olmos, D.; Gomes, A. J. P. D. S; Roubaud, G.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer
    Meeting Abstract

    Morris, M. J.; Armstrong, A. J.; Chi, K. N. N.; de Bono, J. S.; Herrmann, K.; Krause, B.; Rahbar, K.; Sartor, O.; Tagawa, S. T.; Nagarajah, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results
    Meeting Abstract

    Laccetti, A. L.; Chatta, G.; Kyriakopoulos, C.; Iannotti, N.; Hotte, S. J.; Markowski, M. C.; Pili, R.; Vuky, J.; Zhang, J.; Saad, F.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Clinical and translational data from the phase I SURPASS trial of ADP-A2M4CD8 T cell receptor (TCR) T cell therapy alone or combined with nivolumab in solid tumors
    Meeting Abstract

    Garcia, V. M.; Calvo, E.; Asch, A.; Butler, M.; Zugazagoitia, J.; Charlson, J.; Cervantes, A.; Van Tine, B.; Aggen, D.; Clarke, J.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save